# Fibrinolytic Pathways {-}

## **Overview of Fibrinolysis** {-}

*   **Definition:** The process by which fibrin clots are broken down and removed from blood vessels once tissue repair has occurred
*   **Purpose:** To restore normal blood flow, prevent excessive clot formation, and maintain vascular patency
*   **Key Components:**
    *   Plasminogen
    *   Plasmin
    *   Plasminogen Activators
    *   Plasmin Inhibitors
    *   Fibrin Degradation Products (FDPs)

## **Components of the Fibrinolytic System** {-}

*   **Plasminogen:**

    *   *Definition:* An inactive zymogen (precursor) synthesized in the liver and found in the plasma and other body fluids
    *   Structure: A single-chain glycoprotein
    *   Function: When activated, plasminogen is converted to plasmin, the primary enzyme responsible for breaking down fibrin
    *   Binding to Fibrin: Plasminogen binds to fibrin, making it available for activation at the site of the clot

*   **Plasmin:**

    *   *Definition:* An active serine protease enzyme that degrades fibrin, leading to clot breakdown
    *   Formation: Formed by the activation of plasminogen through plasminogen activators
    *   Function:
        *   Degradation of Fibrin: Breaks down fibrin into fibrin degradation products (FDPs)
        *   Degradation of Other Proteins: Plasmin can also degrade other proteins, including fibrinogen, factors V and VIII, and other components of the coagulation system
*   **Plasminogen Activators:**
    *   *Definition:* Enzymes that convert plasminogen to plasmin
    *   Key Plasminogen Activators:
        *   Tissue Plasminogen Activator (tPA):
            *   Synthesized and released by endothelial cells
            *   Most active when bound to fibrin
            *   Plays a key role in dissolving clots within blood vessels
        *   Urokinase Plasminogen Activator (uPA):
            *   Found in various tissues and body fluids
            *   Activates plasminogen in the extravascular space
        *   Streptokinase:
            *   Exogenous plasminogen activator produced by streptococcal bacteria
            *   Used therapeutically as a thrombolytic agent
*   **Plasmin Inhibitors:**
    *   *Definition:* Proteins that regulate the activity of plasmin and plasminogen activators
    *   Key Inhibitors:
        *   Alpha-2-Antiplasmin (α2-AP):
            *   The primary inhibitor of plasmin
            *   Rapidly inactivates plasmin that is free in the circulation, preventing it from degrading other proteins
            *   Forms a stable complex with plasmin, which is then cleared from the circulation
        *   Plasminogen Activator Inhibitor-1 (PAI-1):
            *   The primary inhibitor of tPA and uPA
            *   Produced by endothelial cells, platelets, and other tissues
        *   Thrombin Activatable Fibrinolysis Inhibitor (TAFI):
            *   TAFI, when activated by thrombin, modifies fibrin to make it less susceptible to plasminogen binding and subsequent degradation by plasmin.
*   **Fibrin Degradation Products (FDPs):**
    *   *Definition:* Fragments produced when plasmin degrades fibrin
    *   Examples:
        *   D-dimer: A specific marker for cross-linked fibrin degradation
        *   Fibrin monomers
        *   Fragment X, Fragment Y, Fragment D, and Fragment E
    *   Cleared from the circulation by the liver and kidneys

## **Process of Fibrinolysis** {-}

1.  **Clot Formation:**
    *   The coagulation cascade is activated, leading to the formation of a fibrin clot at the site of vascular injury
2.  **Plasminogen Binding:**
    *   Plasminogen binds to the fibrin clot
3.  **tPA Release:**
    *   Endothelial cells release tPA, which also binds to fibrin
4.  **Plasmin Activation:**
    *   tPA activates plasminogen to plasmin on the surface of the fibrin clot
5.  **Fibrin Degradation:**
    *   Plasmin degrades fibrin into fibrin degradation products (FDPs), including D-dimer
6.  **Inhibition:**
    *   α2-AP rapidly inactivates any plasmin that escapes from the clot into the circulation, preventing it from degrading other proteins
    *   PAI-1 inhibits tPA and uPA
    *   TAFI inhibits plasminogen binding
7.  **Clearance:**
    *   FDPs are cleared from the circulation by the liver and kidneys

## **Regulation of Fibrinolysis** {-}

*   **Localized Activation:** tPA is most active when bound to fibrin, which ensures that plasmin is primarily generated at the site of the clot
*   **Inhibition:** PAI-1 and α2-AP inhibit the activity of plasminogen activators and plasmin, respectively
*   **TAFI** Thrombin-activatable fibrinolysis inhibitor inhibits the activity of plasminogen activator.

**Clinical Significance**

*   **Thrombosis:** Impaired fibrinolysis can lead to excessive clot formation and thrombosis (e.g., deep vein thrombosis, pulmonary embolism)
*   **Bleeding:** Excessive fibrinolysis can lead to bleeding disorders (e.g., disseminated intravascular coagulation, DIC)
*   **Therapeutic Use:** Fibrinolytic agents (like tPA and streptokinase) are used to treat thromboembolic disorders (e.g., myocardial infarction, stroke)

## **Laboratory Testing** {-}

*   **D-dimer Assay:**

    *   Measures the level of D-dimer in the blood
    *   Elevated in conditions with increased fibrinolysis (e.g., DVT, PE, DIC)
    *   Used as a screening test for venous thromboembolism (VTE)
*   **Fibrinogen Level:**

    *   Measures the amount of fibrinogen in the blood
    *   Decreased in conditions with excessive fibrinolysis (e.g., DIC)
*   **tPA and PAI-1 Assays:**

    *   Measure the levels of tPA and PAI-1 in the blood
*   **Euglobulin Lysis Time:**
    *   Assesses global fibrinolytic activity.

## **Key Terms** {-}

*   **Fibrinolysis:** The breakdown of fibrin clots
*   **Plasminogen:** Inactive precursor to plasmin
*   **Plasmin:** Active enzyme that degrades fibrin
*   **tPA (Tissue Plasminogen Activator):** Plasminogen activator released by endothelial cells
*   **uPA (Urokinase Plasminogen Activator):** Plasminogen activator found in various tissues and body fluids
*   **α2-Antiplasmin (α2-AP):** Primary inhibitor of plasmin
*   **PAI-1 (Plasminogen Activator Inhibitor-1):** Inhibitor of tPA and uPA
*   **TAFI** Thrombin-activatable fibrinolysis inhibitor: inhibits the activity of plasminogen activator.
*   **Fibrin Degradation Products (FDPs):** Fragments produced when plasmin degrades fibrin
*   **D-dimer:** A specific marker for cross-linked fibrin degradation
